Search research articles
Contact Us
Filters
Showing results (61-70 of 73) with videos related to
Page
of 8
Sort By:
The Journal of Thoracic and Cardiovascular Surgery
|
February 1, 1991
Is there ever a role for salvage operations in limited small-cell lung cancer?
F A Shepherd, R Ginsberg, G A Patterson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 24, 2017
Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27
K Strasser-Weippl, G Sudan, R Ramjeesingh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 1995
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen
P E Goss, R M Clark, U Ambus, et al.
British Journal of Cancer
|
September 19, 2014
Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy
Y Chavarri-Guerra, M J Higgins, J Szymonifka, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2005
The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)
K M Wasan, P E Goss, P H Pritchard, et al.
Breast (Edinburgh, Scotland)
|
November 29, 2016
Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011
Y Chavarri-Guerra, J St Louis, A Bukowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 28, 2002
Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement
A U Buzdar, S E Come, A Brodie, et al.
Breast Cancer Research and Treatment
|
February 24, 2001
Liarozole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer
P E Goss, K Strasser, R Marques, et al.
Breast Cancer Research and Treatment
|
January 12, 2011
A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women
T Cigler, H Richardson, M J Yaffe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 1998
Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen
E Warner, D Hedley, I Andrulis, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 73) with videos related to
Sort By:
Page
of 8
The Journal of Thoracic and Cardiovascular Surgery
|
February 1, 1991
Is there ever a role for salvage operations in limited small-cell lung cancer?
F A Shepherd, R Ginsberg, G A Patterson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 24, 2017
Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27
K Strasser-Weippl, G Sudan, R Ramjeesingh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 1995
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen
P E Goss, R M Clark, U Ambus, et al.
British Journal of Cancer
|
September 19, 2014
Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy
Y Chavarri-Guerra, M J Higgins, J Szymonifka, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2005
The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)
K M Wasan, P E Goss, P H Pritchard, et al.
Breast (Edinburgh, Scotland)
|
November 29, 2016
Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011
Y Chavarri-Guerra, J St Louis, A Bukowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 28, 2002
Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement
A U Buzdar, S E Come, A Brodie, et al.
Breast Cancer Research and Treatment
|
February 24, 2001
Liarozole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer
P E Goss, K Strasser, R Marques, et al.
Breast Cancer Research and Treatment
|
January 12, 2011
A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women
T Cigler, H Richardson, M J Yaffe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 1998
Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen
E Warner, D Hedley, I Andrulis, et al.
Page
of 8